Zacks: Analysts Anticipate Karyopharm Therapeutics Inc (NASDAQ:KPTI) Will Post Earnings of -$0.97 Per Share
Equities analysts expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will report earnings per share of ($0.97) for the current quarter, Zacks reports. Three analysts have made estimates for Karyopharm Therapeutics’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.15). Karyopharm Therapeutics posted earnings of ($0.60) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 61.7%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full year earnings of ($3.79) per share for the current financial year, with EPS estimates ranging from ($4.79) to ($3.30). For the next year, analysts anticipate that the firm will report earnings of ($2.71) per share, with EPS estimates ranging from ($4.80) to ($1.58). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.75 million. Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%.
Several institutional investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of Karyopharm Therapeutics by 31.3% in the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock valued at $95,000 after acquiring an additional 2,411 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after acquiring an additional 3,300 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Karyopharm Therapeutics by 20.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock valued at $419,000 after acquiring an additional 3,400 shares in the last quarter. Weiss Multi Strategy Advisers LLC lifted its position in shares of Karyopharm Therapeutics by 24.4% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the company’s stock valued at $234,000 after acquiring an additional 4,905 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Karyopharm Therapeutics by 169,300.0% in the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after acquiring an additional 10,158 shares in the last quarter. Institutional investors and hedge funds own 84.20% of the company’s stock.
NASDAQ KPTI traded up $0.37 on Wednesday, hitting $8.40. 118,734 shares of the company traded hands, compared to its average volume of 4,558,527. The firm has a market cap of $488.74 million, a P/E ratio of -2.67 and a beta of 2.44. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.98. The business has a 50 day simple moving average of $6.37. Karyopharm Therapeutics has a 52-week low of $3.92 and a 52-week high of $21.71.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Featured Article: Management Fee
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.